Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
Holding ARGX?
Track your performance easily
ARGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$327.73 - $552.83
Previous Close$542
Volume548.88K
Average Volume (3M)356.90K
Market Cap
$32.26B
Enterprise Value$30.23B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Oct 24, 2024EPS Estimate
$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding59,194,488
10 Day Avg. Volume281,140
30 Day Avg. Volume356,901
Standard Deviation0.12
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)8.08
Price to Sales (P/S)78.86
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue141.80
Enterprise Value/Gross Profit27.27
Enterprise Value/Ebitda-66.28
Forecast
1Y Price Target
$548.37Price Target Upside1.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Argenx Se News
Bulls Say, Bears Say
Bulls Say
Drug Growth PotentialVyvgart will be the fastest growing drug in both MG and CIDP, driven by high levels of physician awareness and favorable perceived clinical profile relative to other drugs.
Market ExpansionTreating seronegative and ocular MG patients could double the MG opportunity.
Strong Sales Performance2Q24 revenue of $489M far higher than consensus of $439M.
Bears Say
Clinical ApproachesThe surprising clinical setbacks led the company to rethink clinical approaches in clinical development.
Clinical DataNipo's clinESSDAI and ESSDAI doesn't seem competitive vs what we've seen historically.
Safety And Tolerability15 mg/kg Q2W nipocalimab had numerical albumin drops and LDL increases, which haven't been seen with Vyvgart.
---
Ownership Overview
0.00%
Insiders
26.24% Mutual Funds
28.41% Other Institutional Investors
45.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $327.73 and its highest was $552.83 in the past 12 months.
What is Argenx Se’s market cap?
Currently, no data Available
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Oct 24, 2024 which is in 46 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Jul 25, 2024. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of -$0.9 by $1.35.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is $0.1.
How many shares outstanding does Argenx Se have?
Argenx Se has 59,796,272 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $0.45 in its last earnings report, beating expectations of -$0.9. Following the earnings report the stock price went up 4.731%.
Which hedge fund is a major shareholder of Argenx Se?
Among the largest hedge funds holding Argenx Se’s share is Baker Bros Advisors LP. It holds Argenx Se’s shares valued at 48M.
---
Argenx Se Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$548.37 (1.18% Upside)
$548.37 (1.18% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 26.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.74%
12-Months-Change
Fundamentals
Return on Equity
-5.75%
Trailing 12-Months
Asset Growth
50.18%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
ARGX Earnings Call
Q2 2024
0:00 / 0:00
---
ARGX Stock 12 Month Forecast
Average Price Target
$548.37
▲(1.18% Upside)
Technical Analysis
Best Analysts Covering ARGX
1 Year
1 Year Success Rate
15/16 ratings generated profit
1 Year Average Return
+26.27%
reiterated a buy rating 3 months ago
Copying Allison Bratzel's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +26.27% per trade.
---